Literature DB >> 11484399

[Procalcitonin in pyelonephritis and acute community-acquired pneumonia in adults].

M Martinot1, Y Hansmann, S De Martino, O Lesens, G Coumaros, E Pencreach, M Bertrand, D Christmann.   

Abstract

OBJECTIVES: Procalcitonin (PCT) is an acute-phase protein involved in the specific inflammatory reaction to severe bacterial or fungal infections. This protein does however lack sensitivity in focal infections. PATIENTS AND METHODS: In this study, we investigated PCT, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), leukocytosis, and fibrinogen levels at admission among adult patients hospitalized for community-acquired pneumonia (n = 33) or pyelonephritis (n = 30) and in a control population (n = 27) of patients with viral infections and non-infectious inflammatory diseases.
RESULTS: Median serum PCT in the control group (0.21 ng/ml) was significantly lower than in the pyelonephritis group (0.46 ng/ml, p < 0.0005) or the pneumonia group (0.88 ng/ml, p < 0.0005). In the control group, median CRP was 51.4 ng/l reaching 220 mg/l in the pyelonephritis and 198 mg/l in the pneumonia group (p < 0.0005 in both cases). The other markers of inflammation investigated (leukocytosis, ESR, fibrinogen) did not show such differences between the control group and the sepsis groups. The sensitivity of PCT (threshold 0.5 ng/ml) was 61% for the diagnosis of pneumonia and 44% for the diagnosis of pyelonephritis. Specificity was 92% in both cases. In comparison, the sensitivity of CRP (threshold 50 mg/l) was 94% and 91% for pyelonephritis and pneumonia respectively with a 33% specificity in both cases.
CONCLUSION: PCT is a specific but poorly sensitive marker of community-acquired pneumonia and pyelonephritis among adults hospitalized in medical wards.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484399

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes.

Authors:  Ali A El-Solh; Hardik Vora; Paul R Knight; Jahan Porhomayon
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

Review 2.  Biomarkers in the diagnosis of aspiration syndromes.

Authors:  Philippe Abou Jaoude; Paul R Knight; Patricia Ohtake; Ali A El-Solh
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

3.  Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study.

Authors:  Shahin Gaïni; Ole Graesbøll Koldkjaer; Court Pedersen; Svend Stenvang Pedersen
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.